
Human Disintegrin and metalloproteinase domain-containing protein 17 250-258, YLIELIDRV
Description
About Human Disintegrin and metalloproteinase domain-containing protein 17 250-258, YLIELIDRV
The Human Disintegrin and metalloproteinase domain-containing protein 17 Peptide (IEDB: 450202) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Disintegrin and metalloproteinase domain-containing protein 17 Peptide, H-YLIELIDRV-OH (Uniprot: P78536 aa: 250-258) from JPT is produced under strict quality control and quality management.
Human Disintegrin and metalloproteinase domain-containing protein 17 250-258, YLIELIDRV - Specifications
- Peptide sequence: H-YLIELIDRV-OH
- Amount: 10 mg (10 x 1 mg)
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Ovarian cancer, Breast cancer, Prostate cancer
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Request a Quote for you custom antigen peptide!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human Disintegrin and metalloproteinase domain-containing protein 17 250-258, YLIELIDRV
References:
Read References with JPT’s Antigen Peptides
Human Disintegrin and metalloproteinase domain-containing protein 17 250-258, YLIELIDRV has been described in:
ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers., Clin Exp Immunol, 2011 (PMID: 21175594)
First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients., J Transl Med, 2012 (PMID: 22862954)
Documentation
Documentation for Human Disintegrin and metalloproteinase domain-containing protein 17 250-258, YLIELIDRV
Properties
Properties of Human Disintegrin and metalloproteinase domain-containing protein 17 250-258, YLIELIDRV
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Breast cancer, Ovarian cancer, Prostate cancer |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human Disintegrin and metalloproteinase domain-containing protein 17 250-258, YLIELIDRV
Information | Values |
---|---|
Sequence: | H-YLIELIDRV-OH |
Specifications: | 9mer peptide as TFA salt |